Thale Dawn Hovdun Patrick-BrownOslo University Hospital · Division of Surgery, Inflammatory Diseases and Transplantation
Thale Dawn Hovdun Patrick-Brown
BSc, MSc MIET CandPhD
EU-SolidAct
AXL-SolidAct
Bari-SolidAct
About
8
Publications
922
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
85
Citations
Introduction
Thale is a professional medical research project and clinical trials manager working with the SolidAct COVID-19 trial (Trøseid Group, Oslo University Hospital, Clinic for Surgery, Inflammation Medicine and Transplantation - KIT), and the Molecular Mechanisms of Ageing group (Evandro F. Fang, Akershus University Hospital/University of Oslo).
Additional affiliations
March 2021 - present
August 2020 - present
Orthrus Project Management AS
Position
- CEO
May 2020 - present
Education
September 2012 - April 2018
September 2005 - April 2008
September 1998 - March 2002
Publications
Publications (8)
Background
The new European Medicines Agency (EMA) Clinical Trials Information System (CTIS), based on the Clinical Trials Regulation (CTR EU 536/2014), came into full effect on 31 January 2022 and was intended to provide an easier, more streamlined approach to the registration of clinical trials taking place in Europe. Using the experience gained...
![Clinical data reported (red – not reported; green – reported) [17–57]....](publication/369403010/figure/fig3/AS:11431281138455601@1680748328291/Clinical-data-reported-red-not-reported-green-reported-17-57-Abbreviations-see_Q320.jpg)
Objectives
Pseudomyxoma peritonei (PMP) is a rare cancer currently affecting over 11,736 patients across Europe. Since PMP is so uncommon, collaboration between scientific centers is key to discovering the mechanisms behind the disease, efficient treatments, and targets pointing to a cure. To date, no consensus has been reached on the minimum data...
Background
The new European Medicines Agency (EMA) Clinical Trials Information System (CTIS), based on the Clinical Trials Regulation (CTR EU 536/2014), came into full effect on 31 January 2022 and was intended to provide an easier, more streamlined approach to the registration of clinical trials taking place in Europe. Using the experience gained...
Background
Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants.
Methods
Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to Ma...
While extracellular Aβ plaques and intracellular tau tangles are the classical disease-defining pathological features of Alzheimer’s disease (AD), defective mitophagy, and consequently, the accumulation of damaged mitochondria increase risk of AD and exacerbate AD progression. Mitophagy is a cellular autophagic process that selectively recognizes a...
Background
The determination of the incidence and prevalence of rare diseases is important for economists and health-care providers. Pseudomyxoma peritonei (PMP) is a rare, slow-growing abdominal cancer that represents a substantial burden on both patients and health-care systems. The incidence rate was previously approximated at 1–2 people per mil...
Background and purpose:
We investigated how features relating to pelvic cavity anatomy and tumor hemodynamic factors may influence systemic failure in rectal cancer.
Materials and methods:
Rectal cancer patients (207 women, 343 men), who had been prospectively enrolled onto six cohorts and given curative-intent therapy, were analyzed for the fir...
